In MM cells, which are highly dependent on transcriptional regulation, pomalidomide inhibits NF-κB activity and thereby suppresses COX-2 gene transcription, an action that contributes to its therapeutic efficacy [454]. This evidence concerns the gene NFKB1 and Miyoshi myopathy.